31 human secreted proteins
    2.
    发明公开
    31 human secreted proteins 审中-公开
    31 menschliche sekretierte蛋白

    公开(公告)号:EP1491550A1

    公开(公告)日:2004-12-29

    申请号:EP04008021.0

    申请日:1999-11-09

    摘要: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

    摘要翻译: 人类分泌的多核苷酸及其编码的蛋白质是新的。 独立权利要求包括以下内容:(1)分离的核酸分子(I),其包含具有与以下序列之一至少95%相同的核苷酸序列的多核苷酸:(a)31个定义的基因之一的多核苷酸片段 说明书中给出的序列(A)或包含在与(A)可杂交的31个ATCC沉积物(C)之一中的cDNA序列的多核苷酸片段; (b)编码本说明书中给出的31个定义序列(B)之一的多肽片段或(C)的多核苷酸片段的多核苷酸; (c)编码(B)的多肽结构域或由(C)编码的多肽结构域的多核苷酸; (d)编码(B)的多肽表位或由(C)编码的多肽表位的多核苷酸; (e)编码具有生物活性的(B)的多肽或(C)所包含的cDNA序列的多核苷酸的多核苷酸; (f)作为(A)的变体的多核苷酸; (g)作为(A)的等位变体的多核苷酸; (h)编码(B)的物种同系物的多核苷酸; 或(i)能够在严格条件下与(a) - (h)的多核苷酸中的任一种杂交但不与仅具有A或T残基的核苷酸序列的核酸分子杂交的多核苷酸; (2)包含(I)的重组载体; (3)制备包含(I)的重组宿主细胞的方法; (4)通过(3)的方法制备的重组宿主细胞; (5)分离的多肽(II),其包含与以下序列之一至少95%相同的氨基酸序列:(a)(B)的多肽片段或(C)中包含的编码序列; (b)(B)的多肽片段或(C)中包含的具有生物活性的编码序列; (c)(B)的多肽表位或(C)中包含的编码序列; (d)(B)的分泌形式或(C)中包含的编码序列; (e)(B)的全长蛋白质或(C)中包含的编码序列; (f)(B)的变体; (g)(B)的等位基因变体; 或(h)(B)的物种同源物; (6)特异性结合(II)的分离抗体; (7)表达(II)的重组宿主细胞; (8)制备(II)的方法,包括在使多肽表达并回收多肽的条件下培养(7)的重组宿主细胞; (9)用于诊断受试者的病理状况或病理状态敏感性的方法,包括:(I)中确定是否存在突变并基于突变的存在或不存在进行诊断; (10)用于诊断受试者的病理状况或病理状态敏感性的方法,包括测定生物样品中(II)的表达的存在或数量,并基于蛋白质的表达的存在或数量进行诊断 ; (11)鉴定与(II)的结合伴侣的方法,包括使(II)与结合配偶体接触并确定对(II)的活性的任何影响; (12)对应于(C)的cDNA序列的基因; (13)鉴定生物测定中的活性的方法,包括在宿主细胞中表达(A),分离上清液,检测生物测定中的活性并用活性鉴定上清液中的蛋白质; 和(14)通过(13)的方法鉴定的产物。 活动:细胞抑制 增殖; 抗过敏; 皮肤; 免疫抑制; 抗心律不整; Cardiant; 伤药; 抗菌; 杀病毒。 在含有4%胎牛血清(FBS),16单位/ ml肝素和50单位/ ml内皮细胞生长的M199培养基中,将人脐静脉内皮细胞(HUVEC)以2-5×10 4个细胞/ 35mm培养皿密度接种 补充剂。 第二天,用含有10%FBS和8单位/ ml肝素的M199代替培养基。 具有氨基酸序列(B)和阳性对照例如 以各种浓度加入碱性成纤维细胞生长因子(bFGF)。 培养基在第4天和第6天更换,第8天用Coulter计数器测定细胞数。 HUVEC细胞数量的增加将表明本发明的多肽增殖血管内皮细胞。 没有结果。 作用机制:基因治疗。

    Fc receptors and polypeptides
    5.
    发明公开
    Fc receptors and polypeptides 失效
    Fc受体

    公开(公告)号:EP1712631A3

    公开(公告)日:2009-01-21

    申请号:EP06010773.7

    申请日:1998-01-20

    CPC分类号: C07K14/70535

    摘要: The present invention relates to five novel Fc receptor-like proteins which are members of the Fc Receptor family. In particular, isolated nucleic acid molecules are provided encoding the human FcR-I, FcR-II, FcR-III, FcR-IV and FcR-V proteins. FcR-I, FcR-II, FcR-III, FcR-IV and FcR-V polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of FcR-I, FcR-II, FcR-III, FcR-IV and FcR-V activities. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

    Neutrokine alpha
    7.
    发明公开
    Neutrokine alpha 失效
    Neutrokin阿尔法

    公开(公告)号:EP1577391A1

    公开(公告)日:2005-09-21

    申请号:EP05012261.3

    申请日:1996-10-25

    摘要: The present invention relates to a novel Neutrokine alpha protein which is a member of the TNF protein family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine alpha protein including soluble forms of the extracellular domain. Neutrokine alpha polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine alpha activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.